Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment.
作者信息
Mima Yoshihito, Yamamoto Masako, Iozumi Ken
机构信息
Department of Dermatology, Tokyo Metropolitan Police Hospital, Tokyo, Japan.
出版信息
Acta Derm Venereol. 2025 Jun 16;105:adv43419. doi: 10.2340/actadv.v105.43419.
Abstract
摘要
相似文献
1
Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment.
Acta Derm Venereol. 2025 Jun 16;105:adv43419. doi: 10.2340/actadv.v105.43419.
2
Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study.
Br J Dermatol. 2025 Jun 20;193(1):56-65. doi: 10.1093/bjd/ljaf045.
3
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316.
4
Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.
Br J Dermatol. 2024 Jul 16;191(2):200-208. doi: 10.1093/bjd/ljae131.
5
A critical evaluation of nemolizumab for prurigo nodularis.
Expert Rev Clin Immunol. 2024 Jun;20(6):577-587. doi: 10.1080/1744666X.2024.2306225. Epub 2024 Jan 19.
6
Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis.
Skin Therapy Lett. 2025 May;30(3):1-3.
7
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.
8
Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Actas Dermosifiliogr. 2022 Jul-Aug;113(7):674-684. doi: 10.1016/j.ad.2021.12.014. Epub 2021 Dec 23.
9
Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis.
J Allergy Clin Immunol. 2024 Jan;153(1):93-94. doi: 10.1016/j.jaci.2023.11.003. Epub 2023 Nov 10.
10
Dupilumab for pediatric prurigo nodularis: A case report.
Pediatr Dermatol. 2021 Jan;38(1):334-335. doi: 10.1111/pde.14464. Epub 2020 Nov 28.
本文引用的文献
1
Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib - A prospective single-arm investigational study.
Indian J Dermatol Venereol Leprol. 2025 Jan 17:1-6. doi: 10.25259/IJDVL_1017_2024.
2
Pathophysiology of Prurigo Nodularis: Neuroimmune Dysregulation and the Role of Type 2 Inflammation.
J Invest Dermatol. 2025 Feb;145(2):249-256. doi: 10.1016/j.jid.2024.06.1276. Epub 2024 Aug 30.
3
IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice.
Exp Dermatol. 2024 Jun;33(6):e15115. doi: 10.1111/exd.15115.
4
Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial.
JAMA Dermatol. 2024 Jul 1;160(7):717-724. doi: 10.1001/jamadermatol.2024.1464.
5
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks.
J Clin Med. 2024 Feb 2;13(3):878. doi: 10.3390/jcm13030878.
6
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.
7
Dupilumab as a novel treatment option for prurigo nodularis.
J Allergy Clin Immunol. 2023 Oct;152(4):870-872. doi: 10.1016/j.jaci.2023.08.011. Epub 2023 Aug 23.
8
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Nat Med. 2023 May;29(5):1180-1190. doi: 10.1038/s41591-023-02320-9. Epub 2023 May 4.
9
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1820-1825. doi: 10.1111/jdv.18377. Epub 2022 Jul 4.
10
Prurigo Nodularis: Review and Emerging Treatments.
Skin Therapy Lett. 2021 May;26(3):5-8.
Zotero 插件